Inotiv's Q2 Loss Per Share More Than Doubles to ($0.94) Amid Revenue Decline
Summary
Inotiv, Inc. reported significantly deteriorated second-quarter 2026 results, with diluted loss per share more than doubling to ($0.94) from ($0.44) in the prior year, and net loss widening to ($32.47M). Revenue also declined 5.4% year-over-year to $117.65M. These poor financial outcomes follow the company's recent temporary waiver from a minimum liquidity covenant and prior 'going concern' warnings, underscoring severe financial challenges. For a micro-cap company already facing liquidity issues, this substantial increase in losses and revenue decline is highly material and raises further concerns about its operational stability and ability to meet future obligations. Traders will be closely monitoring the company's ability to address its financial distress and achieve profitability.
At the time of this announcement, NOTV was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.22 to $3.32. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.